Nuveen LLC Takes $2.02 Million Position in Vanda Pharmaceuticals Inc. $VNDA

Key Points

• Nuveen LLC has acquired 440,561 shares of Vanda Pharmaceuticals, representing a 0.75% ownership stake, valued at approximately $2,022,000.
• Vanda Pharmaceuticals reported a loss of $0.46 earnings per share (EPS) for its last quarter, which was below analysts' expectations of $0.34 EPS.
• Research firms have varying outlooks on Vanda, with HC Wainwright issuing a "buy" rating and a target price of $20.00, while Wall Street Zen has downgraded the stock to a "strong sell" rating.

Nuveen LLC purchased a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 440,561 shares of the biopharmaceutical company's stock, valued at approximately $2,022,000. Nuveen LLC owned about 0.75% of Vanda Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Quantinno Capital Management LP acquired a new position in Vanda Pharmaceuticals in the fourth quarter valued at approximately $48,000. Linden Thomas Advisory Services LLC acquired a new position in Vanda Pharmaceuticals during the 1st quarter valued at approximately $49,000. Virtu Financial LLC bought a new position in Vanda Pharmaceuticals during the 1st quarter worth $72,000. ProShare Advisors LLC increased its position in Vanda Pharmaceuticals by 32.4% in the fourth quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 4,599 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in Vanda Pharmaceuticals by 17.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 3,370 shares during the period. Institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Stock Down 1.7%

Vanda Pharmaceuticals stock traded down $0.08 during midday trading on Thursday, hitting $4.64. The company's stock had a trading volume of 575,868 shares, compared to its average volume of 430,313. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $5.55. The company has a market capitalization of $274.18 million, a PE ratio of -4.11 and a beta of 0.74. The stock's 50-day moving average price is $4.64 and its 200-day moving average price is $4.54.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%.The business had revenue of $52.59 million during the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on VNDA shares. Wall Street Zen lowered shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 2nd. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Thursday, August 21st. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Strong Buy" and an average price target of $16.50.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 7,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the sale, the director directly owned 97,082 shares of the company's stock, valued at $445,606.38. This represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 10.00% of the stock is currently owned by corporate insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.